Organigram Reports Second Quarter Fiscal 2026 Results
Organigram’s core Canadian business stumbles into the red just as its landmark Sanity Group deal closes, leaving investors to wonder if the European cure will be enough to offset domestic decay.
Organigram reported Q2 Fiscal 2026 results for the period ended March 31, 2026, post-market on May 11, 2026. Gross revenue fell 9% year-over-year to $93.3 million, net revenue dropped 9% to $59.8 million, and adjusted EBITDA collapsed 82% to $0.9 million. The company swung to a net loss of $0.9 million from a $42.5 million profit a year earlier. Management blamed underperformance in vapes, temporary challenges in infused pre‑roll production, and slower industry growth. The quarter’s adjusted gross margin slipped to 31% from 33%, while SG&A rose to $23.6 million, partly due to a wholesale customer insolvency credit loss. Free cash flow remained negative at an outflow of $7.0 million.
The release also confirmed the post‑quarter close of the Sanity Group GmbH acquisition and the simultaneous closing of the BAT private placement and $60 million senior secured credit facilities. Because of the Sanity addition, full‑year Fiscal 2026 net revenue guidance is raised to over $350 million (from over $300 million), with adjusted EBITDA and gross margins expected to exceed Fiscal 2025 levels, and free cash flow approximating breakeven.
The Q2 results reveal a material deterioration in the legacy domestic business that was not fully telegraphed in the upbeat Q1 narrative. In Q1, management explicitly reaffirmed >$300 million full‑year revenue guidance and pointed to margin expansion. Yet Q2’s net revenue of $59.8 million implies a sharply lower run rate and, absent Sanity, would likely miss the original target. The 82% EBITDA plunge and unexpected net loss – despite a non‑cash boost from derivative revaluations in Q1 – signal that competitive and operational headwinds are more severe than previously disclosed. The raised full‑year guidance is entirely attributable to the acquired Sanity revenue, masking organic weakness. While the Sanity deal is strategically transformative, the Q2 earnings print introduces material downside risk to the near‑term outlook, particularly if the Sanity integration encounters delays or margin pressure. This qualifies as Material – Negative because it presents genuinely new, market‑moving adverse information that reverses the positive momentum implied by earlier communications.
Organigram Global Inc. is a Canadian licensed cannabis producer with the #1 recreational market share nationally. Its flagship indoor cultivation facility in Moncton, New Brunswick, uses seed‑based genetics and advanced lighting to achieve high‑THC yields. The company expanded into vapes, edibles, and beverages through acquisitions of Motif Labs and Collective Project. The recent acquisition of Germany’s Sanity Group gives it a vertically integrated European hub, with medical cannabis distribution in Germany, retail pilots in Switzerland, and early‑stage footprints in the UK, Poland, and Czechia. International growth, particularly in the German medical market, is now the central strategic pillar.